Download the Article
CRO and Biotech Discuss Advancements in Radiotherapy
CRO and Biotech Discuss Advancements in Radiotherapy
The Forefront of Radiopharmaceuticals: CRO and Biotech Discuss Advancements in Radiotherapy
In a recent webinar, Medpace Radiation Oncologist, Radiation Clinical Pharmacologist, was joined by a biotech Molecular Imaging Director, and Academic Medical Physicist to cover considerations in alpha-particle therapy.
While alpha emitter isotope therapy, radium, has been available for over a hundred years, there is renewed promise for targeted alpha therapy in treating advanced and metastatic tumors. There are recent reports showing impressive safety and tumor response with alpha-particle therapy across many solid tumor populations.
Radiation Therapy & Radiopharmaceuticals
An integrated Approach
At Medpace, our integrated team of radiation oncologists and imaging experts accelerate the path to approval through the understanding of radiation biology, dosimetry, clinical, regulatory, operational, and imaging considerations that must be factored in when designing a radiation oncology trial. Our integrated advantages include:
- Cross-disciplinary radiation oncology capabilities providing state-of-the-art services for either stand-alone or fully integrated projects with Medpace CRO
- Board-certified radiation oncologists providing medical leadership to enhance and expedite radiopharmaceutical and radiation device development
- Comprehensive regulatory affairs and operational experts who work collaboratively with our medical team
- Fully-integrated Imaging Core Laboratory services, including expert guidance from our radiation physicists and dosimetrists
